Jina Chung1, Kristina Callis Duffin2, Junko Takeshita3, Daniel B Shin3, Gerald G Krueger2, Andrew D Robertson4, Andrea B Troxel5, Abby S Van Voorhees1, Emily Edson-Heredia6, Joel M Gelfand7. 1. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 2. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah. 3. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 4. National Psoriasis Foundation, Portland, Oregon. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 6. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana. 7. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: joel.gelfand@uphs.upenn.edu.
Abstract
BACKGROUND: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown. OBJECTIVE: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis. METHODS: We conducted a cross-sectional study of patients with plaque psoriasis (N=1153) and palmoplantar psoriasis (N=66) currently receiving systemic or light treatment for psoriasis. RESULTS: Patients with palmoplantar psoriasis were more likely to report Dermatology Life Quality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problems with mobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the preceding week (OR 2.81; 95% CI 1.63-4.85) than those with plaque psoriasis. LIMITATIONS: Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis. CONCLUSION: Patients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
BACKGROUND: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown. OBJECTIVE: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis. METHODS: We conducted a cross-sectional study of patients with plaque psoriasis (N=1153) and palmoplantar psoriasis (N=66) currently receiving systemic or light treatment for psoriasis. RESULTS:Patients with palmoplantar psoriasis were more likely to report Dermatology Life Quality Index scores that correspond to at least a moderate impact on QoL (odds ratio [OR] 2.08; 95% confidence interval [CI] 1.20-3.61); problems with mobility (OR 1.98; 95% CI 1.10-3.58), self-care (OR 3.12; 95% CI 1.24-7.86), and usual activities (OR 2.47; 95% CI 1.44-4.22) on the European Quality of Life-5 Dimensions questionnaire; and heavy topical prescription use of at least twice daily in the preceding week (OR 2.81; 95% CI 1.63-4.85) than those with plaque psoriasis. LIMITATIONS: Our assessment tools may not account for all dimensions of health-related QoL affected by palmoplantar disease, and these results may not be generalizable to patients with milder forms of psoriasis. CONCLUSION:Patients with palmoplantar psoriasis experience greater health-related QoL impairment and are more likely to report heavy use of topical prescriptions than those with moderate to severe plaque psoriasis.
Authors: Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel Journal: J Invest Dermatol Date: 2009-05-21 Impact factor: 8.551
Authors: Adam A Pettey; Rajesh Balkrishnan; Stephen R Rapp; Alan B Fleischer; Steven R Feldman Journal: J Am Acad Dermatol Date: 2003-08 Impact factor: 11.527
Authors: Ladan Afifi; Lindsey Shankle; April W Armstrong; Marc Boas; Alisha Bridges; Vivian Chiguil; Frank Doris; Kristina Callis Duffin; Eric Fielding; Roy Fleischmann; Joel M Gelfand; Matthew Kiselica; Catherine Kiselica; Brian LaFoy; John J Latella; Junko Takeshita; Sarah Truman; Marilyn T Wan; Vickie Wilkerson; Jashin J Wu; Michael P Siegel; Wilson Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2017
Authors: Steven R Feldman; Bernard Goffe; Gary Rice; Matthew Mitchell; Mandeep Kaur; Debbie Robertson; Debra Sierka; Jeffrey A Bourret; Tamara S Evans; Alice Gottlieb Journal: Am Health Drug Benefits Date: 2016-12